Uses mRNA technology to develop respiratory treatments; official disclosures report 2022 financing and a strategic investment from Cipla.
GermanyFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
2 matching companiesShowing 1–2 / 2
Offers oral, nasal, pulmonary, and early-stage sterile formulation development, from feasibility and prototypes through scale-up and clinical manufacturing, addressing low solubility and stability challenges.
United KingdomFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.